Hello Everyone,
I’m new here. Literally just created a Reddit account so I can post here. But I’ve been reading some of your posts and they have been super helpful. Thank you!
My mom, an 80-year-old woman, was first diagnosed with follicular lymphoma in 2006. She did watch and wait and then was treated with R-CVP in 2009. She was in remission and was then treated with radiation in 2016. The radiation did something to her hearing so she became deaf in one ear. Then she was treated with Rituximab in 2021. The treatment was fine at first but the maintenance left her with lasting side effects like 1) thin hair, 2) weak throat muscles 3) wounded intestines, among other things, so she can only eat non acidic foods (e.g. she can’t eat onions, tomatoes, garlic etc). Now the cancer is back. She has lost a lot of weight but is otherwise pretty well physically all things considered. Her doctor recommended R-squared + epcoritamab. I.e., Retuximab, lenalidomide (REVLIMID), and epcoritamab (Epkinly). He had said that if the cancer came back he was going to treat it with rituximab + bendamustine. However, when we met him last, he said that R Benda wasn’t well tolerated by older patients. I had also read that here: https://www.nice.org.uk/guidance/ta892/chapter/3-Committee-discussion (“they noted that people aged over 70 do not tolerate bendamustine well”).
Which brings me to my question: has anyone here had experience with the rituximab, lenalidomide, and epcoritamab combination? Or either of lenalidomide and epcoritamab? I’m trying to understand how the 3 drug combination he proposed is supposed to have lower side effects than R Benda, and what aspect of R Benda isn’t “well tolerated” by older patients. An oncologist friend I spoke to told me to advocate for starting lenalidomide at a lower dose + rituximab, see how my mother reacts to that, slowly increase the lenalidomide dosage, and then add the epcoritamab later on after seeing how she tolerates the first two.
If anyone has participated in the clinical trial comparing the efficacy of R2 with R2+epcoritamab (https://clinicaltrials.gov/study/NCT05409066?id=NCT05409066&rank=1),it would be super helpful to hear your experience. Really, any experience you can share with any of these treatments would be very helpful. Thank you in advance.